However, inherent or acquired resistance to anti-VEGF therapy is frequently observed in tumors, thus illustrating the need for targeting additional angiogenesis pathways to fully exploit the promise of anti-angiogenic cancer therapy. This evidence concerns the gene VEGFA and cancer.